The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.
GLIOMATCH is now a Horizon Europe funded Research and Innovation Action. The project is aimed at improving the outcome of malignant brain tumours in adults and children, as well as better understanding immunotherapy for brain cancer treatment.
By investigating solutions to alleviate the societal impacts of brain cancer, the project aligns with the objectives of the EU Cancer Mission and contributes to the United Nations’ Sustainable Development Goals 2 and 4.
It is a five year project starting in January 2024 and aligning 14 pan-European partners from 10 different member states.
